Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ENDRA Life Sciences (NDRA) Current Assets (2016 - 2025)

ENDRA Life Sciences has reported Current Assets over the past 6 years, most recently at $12.1 million for Q4 2021.

  • Quarterly Current Assets rose 47.35% to $12.1 million in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $12.1 million through Dec 2021, up 47.35% year-over-year, with the annual reading at $12.1 million for FY2021, 47.35% up from the prior year.
  • Current Assets was $12.1 million for Q4 2021 at ENDRA Life Sciences, down from $14.5 million in the prior quarter.
  • Over five years, Current Assets peaked at $18.4 million in Q1 2021 and troughed at $265648.0 in Q1 2017.
  • The 5-year median for Current Assets is $5.3 million (2017), against an average of $6.6 million.
  • Year-over-year, Current Assets skyrocketed 2907.34% in 2017 and then tumbled 86.17% in 2018.
  • A 5-year view of Current Assets shows it stood at $5.9 million in 2017, then grew by 18.15% to $6.9 million in 2018, then decreased by 5.96% to $6.5 million in 2019, then rose by 25.59% to $8.2 million in 2020, then skyrocketed by 47.35% to $12.1 million in 2021.
  • Per Business Quant, the three most recent readings for NDRA's Current Assets are $12.1 million (Q4 2021), $14.5 million (Q3 2021), and $16.3 million (Q2 2021).